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Abstract
Background:  The ABCA1 protein plays a pivotal role in reverse cholesterol transport, by
mediating the generation of HDL particles and removing cellular cholesterol. Both the proper
expression of ABCA1 in the plasma membrane and the internalization along with apoA-I are
required for function. Therefore, we developed a model system to investigate the effect of clinically
relevant drugs on the cell surface appearance of ABCA1.
Results: By retroviral transduction system, we established stable mammalian cell lines expressing
functional and non-functional ABCA1 variants, tagged with an extracellular hemagglutinin epitope.
After characterization of the expression, proper localization and function of different ABCA1
variants, we followed quantitatively their cell surface expression by immunofluorescent staining,
using flow cytometry. As expected, we found increased cell surface expression of ABCA1 after
treatment with a calpain inhibitor, and observed a strong decrease in plasma membrane ABCA1
expression upon treatment with a trans-Golgi transport inhibitor, Brefeldin A. We tested
cholesterol level lowering drugs and other potential inhibitors of ABCA1. Here we demonstrate
that ezetimibe affects ABCA1 cell surface expression only in the case of a functional ABCA1.
Conclusions: Our model system allows a quantitative detection of cell surface expression of
ABCA1, screening of substrates or specific inhibitors, and investigating transport regulation.
Background
Elevated low-density lipoprotein (LDL) cholesterol,
reduced high-density lipoprotein (HDL) cholesterol, and
increased triglyceride levels significantly contribute to the
accumulation of lipids in atherosclerotic lesions. Reverse
cholesterol transport is believed to be crucial for prevent-
ing atherogenesis and hence the development of cardio-
vascular diseases [1,2]. It is commonly accepted that the
ATP-binding cassette protein, ABCA1 plays a pivotal role
in the initial steps of the reverse cholesterol transport
pathway by mediating the interactions of amphiphilic
apolipoproteins (e.g., apoA-I) with cellular lipids to gen-
erate nascent HDL particles thus removing excess cellular
cholesterol [3,4]. Mutations in ABCA1 cause Tangier dis-
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ease, a disorder characterized by very low HDL levels, cho-
lesterol deposition in macrophages, and premature
atherosclerosis [5-7]. There is increasing evidence suggest-
ing a role for ABCA1 not only in the hepatic but also in the
intestinal HDL-production [8].
Therapeutic efforts to raise HDL levels with different drugs
have been promising. Clinical trials tested various statins,
niacin, and ezetimibe alone and in various combinations
to raise plasma HDL- and to reduce the plasma LDL-cho-
lesterol levels [9,10]. Niacin and ezetimibe together with
statins were proven to be the most effective combination
in vivo [11]. However, conflicting results were reported
about the effects of statins on lipid efflux and the modu-
lation of ABCA1 expression in in vitro experiments [12-
16]. Recently, certain types of calcium channel blockers
(CCBs), e.g., verapamil, nifedipine, have been found to be
anti-atherogenic in clinical trials [17,18]. When their
effects on ABCA1 expression were investigated, contradic-
tory results were obtained. These agents either increased
ABCA1 mRNA levels or elevated the protein expression
without affecting the mRNA level, depending on the cel-
lular test system used [19,20].
Similar to other plasma membrane proteins, the cell sur-
face expression of ABCA1 is modulated by a complex
process, which includes transcriptional and post-tran-
scriptional regulation, as well as internalization, degrada-
tion, and recycling [21,22]. There is evidence that not only
sufficient plasma membrane expression but internaliza-
tion along with apoA-I is required for proper function of
ABCA1 [23,24]. Thus, in the present study we aimed to
develop a quantitative in vitro test system, which is suita-
ble for monitoring the plasma membrane level of ABCA1,
independently from direct transcriptional regulation. In
order to generate such an experimental tool, we intro-
duced a hemagglutinin (HA) epitope into the first extra-
cellular loop of ABCA1, and stably expressed this tagged
ABCA1 in various mammalian cell lines, using a constitu-
tive promoter. In addition, to make our method suitable
for studying trafficking processes of ABCA1 in conjunc-
tion with its function, we generated different loss-of-func-
tion mutant variants of the HA-tagged transporter. In the
present study we demonstrate the applicability and relia-
bility of the developed cellular test system, and report the
effects of several pharmaceuticals, which are known to
have cholesterol-lowering effects in vivo. When studying
whether they act through modifying the cell surface
expression of functional ABCA1, we found that among
several drugs, ezetimibe lowers the plasma membrane
level of a functional ABCA1.
Results
Stable expression of HA-tagged ABCA1 variants in 
mammalian cells
Since we aimed to generate different cell lines stably
expressing ABCA1 at moderate levels, we used a bicis-
tronic retroviral vector containing ABCA1 and a neo-
resistance gene (SsA1neoS) as described in [25]. In order
to make our model system suitable for monitoring the cell
surface appearance of ABCA1, we introduced an HA
epitope into the first extracellular loop of ABCA1 [26]. In
addition to the HA-tagged wild type (wt) ABCA1, we gen-
erated three mutant variants containing a methionine-
lysine substitution in either one or both Walker A motifs
(K939 M, K1952 M, and K939 M/K1952 M). These loss-
of-function mutations were shown to impair cholesterol
efflux and apoA-I binding without affecting protein fold-
ing and intracellular routing [27-29]. The assemblies of
various retroviral constructs are shown in Figure 1. Retro-
viral particles were generated by using ecotropic Phoenix
and PG13 packaging cells as described in the Materials
and Methods section. Thereafter MDCKII and HEK293H
cells were transduced and selected with G418 for stable
expression of the transgenes [25,30].
It has been previously reported that ABCA1 expression
rapidly declines in transfected cells after a few passages
[31]. In order to obtain a model system with stable expres-
sion of each HA-tagged ABCA1 variant at comparable lev-
els, we applied two strategies: i) four different clones with
similar expression levels were combined; or ii) the cells,
showing similar HA staining, were sorted by FACS. The
former method (pooling) was used for the transduced
MDCKII cells; whereas the latter (sorting) was used for
HEK293H cells. The ABCA1 mRNA expression level of the
established cell lines was determined by quantitative RT-
PCR, and compared to that of HepG2 cells, macrophage
model cells, i.e. PMA-pretreated Thp-1 cells, and human
monocyte-derived macrophages (MDM). We found that
ABCA1 was moderately over-expressed in our cell lines
(app. 10-40-fold as compared to HepG2); nevertheless
the expression levels were comparable with that of macro-
phages induced by the LXR agonist, T0901317 (Figure
2A). The protein expression level in the generated cell
lines was also monitored through several passages by
Western blot analysis (Figure 2B). Stable transgene expres-
sion was found up to 50 and 20 passages in MDCKII and
HEK293H cells, respectively.
Cellular localization and functional characterization of 
HA-tagged ABCA1 variants
Besides analyzing the total expression levels, we also stud-
ied the cellular localization of ABCA1 variants in the
established cell lines. In the first set of experiments indi-
rect immunofluorescent labeling with anti-HA antibody
was performed in intact cells, and cell surface staining wasBMC Cell Biology 2009, 10:93 http://www.biomedcentral.com/1471-2121/10/93
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detected by flow cytometry. We found comparable plasma
membrane expression levels of all ABCA1 variants in both
MDCKII and HEK293H cells (Figure 3). Similar to total
expression levels of ABCA1 variants, the cell surface
expression was also unaffected up to 50 and 20 passages
in MDCKII and HEK293H cells, respectively.
The subcellular localization of HA-tagged ABCA1 variants
was also studied by immunofluorescent staining followed
by confocal microscopy. Detailed subcellular localization
analysis performed with HEK293H cells clearly demon-
strated that the HA-tagged ABCA1 is expressed predomi-
nantly in the plasma membrane (Figure 4E-F). A minor
intracellular HA-ABCA1 expression was found in the
Golgi-apparatus (Figure 4H-I), and some degree of colo-
calization was seen with an endosomal marker (Figure
4K-L). The subcellular localization of the HA-tagged
ABCA1 variants was also studied in polarized MDCKII.
Staining of Na+/K+  ATPase was used as a basolateral
plasma membrane marker. Similar to previous reports on
the untagged protein [32], the HA-tagged wt ABCA1 was
also localized to the basolateral membrane compartment
Schematic representation of bicistronic retroviral vectors Figure 1
Schematic representation of bicistronic retroviral vectors. The ABCA1 cDNA was inserted behind a spleen focus-
forming virus (SFFV) retroviral LTR following the splice donor (SD) site. The neomycin resistance (neo) cDNA was inserted 
after a splice acceptor (SA) site derived from the genome of the Moloney murine leukemia virus. Hemagglutinin (HA) epitope 
was introduced into the first extracellular loop of the N-terminal transmembrane domain (TMD) of ABCA1 (between residues 
207 and 208). WT: wild type untagged ABCA1 construct; HA-WT: wild type HA-tagged ABCA1 construct; HA-MK: a variant 
with a methionine-lysine substitution (K939 M) in the Walker A motif of the N-terminal nucleotide-binding domain (NBD1); 
HA-KM: methionine-lysine substitution (K1952 M) in the C-terminal nucleotide-binding domain (NBD2); HA-MM: methionine-
lysine substitution in both Walker A motifs (K939 M/K1952 M). A vector containing only the neo cDNA after the SA site was 
used as a negative control (vector).BMC Cell Biology 2009, 10:93 http://www.biomedcentral.com/1471-2121/10/93
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Figure 2 (see legend on next page)
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(Figure 5D-F), indicating that neither the modest overex-
pression nor HA-tagging affect proper localization. Simi-
larly, all non-functional HA-tagged ABCA1 variants
exhibited basolateral localization (Figure 5G-I, J-L, M-O).
To investigate the functional properties of our HA-tagged
ABCA1 variants, we measured the apoA-I-dependent cho-
lesterol efflux and apoA-I binding in the established
model cells. In accordance with previous observations
with the untagged protein [33,34], ABCA1 expression sig-
nificantly elevated the apoA-I-specific cholesterol efflux in
both HEK293H and MDCKII cells (Figure 6A). More
importantly, no difference was observed between the
untagged and the HA-tagged ABCA1 in this respect. It is
noteworthy that the observed apoA-I-dependent choles-
terol efflux was smaller in our case than in preceding
reports, most likely due to the moderated ABCA1 expres-
sion in our cells versus the massive overexpresssion in the
Expression of wild type and mutant HA-tagged ABCA1 variants in HEK293H and MDCKII cells Figure 2 (see previous page)
Expression of wild type and mutant HA-tagged ABCA1 variants in HEK293H and MDCKII cells. A. The mRNA 
expression level of ABCA1 was measured by real time RT-PCR in the parental HEK293H and MDCKII cells, as well as in cells 
expressing the ABCA1 variants. The ABCA1 expression of HepG2 cells were used as a reference for relative mRNA expres-
sion levels. For comparison, ABCA1 mRNA level was also determined in PMA-pretreated Thp-1 cells and in human monocyte-
derived macrophages (MDM). To induce ABCA1 expression, the latter two cell types were treated with 1 μM T0901317, an 
LXR agonist (LXR). Control: original, parental, or non-treated cells; n.d. - not detected. The expression of ABCA1 variants 
were similar in the established cell lines and comparable with that seen in LXR-induced macrophages. B. The protein expres-
sion level of HA-tagged ABCA1 variants was determined using anti-HA antibody by Western blot analysis on whole cell lysates. 
Panels demonstrate representative blots for the variants of HEK293H and MDCKII cells at passage number 5. Each lane con-
tains 15 μg and 40 μg of protein per well from HEK293H and MDCKII cells, respectively. Anti-Na/K ATPase antibody was used 
to control the sample loading. For further details see legend for Figure 1.
Flow cytometry analysis of cell surface expression of wild type and mutant HA-tagged ABCA1 variants Figure 3
Flow cytometry analysis of cell surface expression of wild type and mutant HA-tagged ABCA1 variants. Indirect 
immunofluorescent labeling with anti-HA antibody and anti-mouse IgG antibody conjugated with Alexa 488 was performed 
with intact HEK293H and MDCKII cells expressing the different variants of HA-tagged ABCA1. Representative flow cytometry 
experiments demonstrate the cell surface expression of ABCA1 variants. HA-WT: (black line); HA-MK: (blue line); HA-KM: 
(green line); HA-MM (red line); vector (dotted line). HA-tagged ABCA1 variants showed comparable plasma membrane 
appearance in both MDCKII and HEK293H cells.
HEK MDCK
HA-WT
Vector
HA-KM
HA-MK
HA-MM
HA-ABCA1 Fluorescence
HA-WT
Vector
HA-KM
HA-MK
HA-MM
HA-ABCA1 FluorescenceBMC Cell Biology 2009, 10:93 http://www.biomedcentral.com/1471-2121/10/93
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Subcellular localization of HA-tagged ABCA1 in HEK293H cells Figure 4
Subcellular localization of HA-tagged ABCA1 in HEK293H cells. HEK293H cells expressing the wild type (HA-WT) 
or double mutant variant (HA-MM) of HA-ABCA1 were immunostained with anti-HA antibody and visualized by confocal 
microscopy (green). As a negative control HEK293H cells transduced with the empty vector was used. Various cellular mark-
ers (wheat germ agglutinin, anti-Giantin and anti-EEA1 antibodies, as well as LysoTracker) were used to identify the different 
cell organelles (red), whereas DAPI staining was used to label the nuclei (blue). Both wild type and MM variant of HA-ABCA1 
were localized predominantly in the plasma membrane. The minor intracellular staining colocalized primarily with the Golgi 
marker, and rarely with the endosomes (see white arrows). The scale bars indicate 10 μm.BMC Cell Biology 2009, 10:93 http://www.biomedcentral.com/1471-2121/10/93
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Subcellular localization of HA-tagged ABCA1 variants in polarized MDCKII cells Figure 5
Subcellular localization of HA-tagged ABCA1 variants in polarized MDCKII cells. MDCKII cells expressing the wild 
type (D-F) or mutant variants (G-O) of HA-ABCA1 were grown on a permeable membrane support to form polarized cul-
tures. As a negative control, cells transduced with the neo-containing vector (see Figure 1) were used (A-C). HA-ABCA1 vari-
ants were visualized by immunofluorescent staining of permeabilized cells, using confocal microscopy. ABCA1 protein detected 
by anti-HA antibody is shown in green; staining of Na+/K+ ATPase (red) served as a basolateral plasma membrane marker. Right 
panels depict the overlay. Cross sections are shown at the bottom of each panel; arrows at the side indicate the position of the 
presented xz and xy planes. All HA-tagged ABCA1 variants exhibited similar and clear basolateral plasma membrane localiza-
tion, showing only a low level intracellular staining.BMC Cell Biology 2009, 10:93 http://www.biomedcentral.com/1471-2121/10/93
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transient expression systems used in previous studies. The
apoA-I-dependent cholesterol effluxes from cells express-
ing the KM, KM, or MM mutants were not significantly
different from that seen in the parental cells.
Similar to apoA-I-dependent cholesterol efflux, apoA-I
binding was found to be elevated in cells expressing either
the untagged or HA-tagged ABCA1, whereas it was unaf-
fected in cells expressing the mutant form of HA-ABCA1
(Figure 6B). Since the calpain inhibitor Acetyl-L-Leucyl-L-
Leucyl-L-Norleucinal (ALLN) and cylcosporin A (CsA)
were used in further experiments, we investigated the
effect of these drugs on the apoA-I-binding in the estab-
lished cell lines. We found that ALLN significantly
increased apoA-I-binding in cells expressing either the
untagged or HA-tagged wt ABCA1-expressing, whereas
CsA pretreatment slightly reduced the apoA-I-binding in
these cells. This observation is in good accordance with
previous studies performed with untagged ABCA1 [35-
38], and clearly indicates that HA-tagging did not alter the
function of the protein. ALLN and CsA had no significant
effect on apoAI-binding in the parental cell line and in cell
expressing the mutant form of HA-ABCA1.
In summary, we demonstrated reasonable and stable
expression, correct subcellular localization, as well as
proper function for the HA-tagged ABCA1. Since all three
HA-tagged ABCA1 mutants were proven to be non-func-
tional with normal expression and localization, only the
wild type HA-tagged and the double mutant variant (MM)
were used in further experiments.
Effect of calpain inhibitor, BFA, and apoA-I on cell surface 
expression of ABCA1 variants
In order to demonstrate the applicability of the HA-tagged
ABCA1 variants for monitoring cell surface expression, we
studied the effect of different substances which are known
to influence ABCA1 trafficking and degradation. Since cal-
pain has been shown to participate in ABCA1 degradation
[35-37], the HA-ABCA1-expressing cells were treated with
the calpain inhibitor, ALLN. This drug was expected to ele-
vate the cell surface expression of ABCA1 due to the inhi-
Functional characterization of the HA-tagged ABCA1 Figure 6
Functional characterization of the HA-tagged ABCA1. A. The apoA-I-dependent cholesterol efflux was measured in 
HEK293H and MDCKII cells expressing the untagged (WT) and HA-tagged (HA-WT) ABCA1. As a control the parental cell 
lines were used. Western blots at the bottom, developed with anti-ABCA1 antibody, indicate the expression levels in the stud-
ied cell lines. ABCA1 expression significantly elevated the apoA-I-specific cholesterol efflux in both cell types. HA-tagging did 
not alter the function of ABCA1. n.d. - not detected. B. Binding of Cy5-labeled apoA-I was determined in HEK293H cells 
expressing the untagged (WT), the HA-tagged wild type ABCA1 (HA-WT) and the mutant form of HA-ABCA1 (HA-MM). 
Substantial labeling was observed in cells expressing the untagged and the HA-tagged wild type ABCA1 (colored histograms) as 
compared to parental cells (grey histograms). No apoA-I binding was seen in cells expressing the mutant form of HA-ABCA1. 
4 h pretreatment with the calpain inhibitor, ALLN (50 μM) significantly increased apoA-I-binding in both untagged and HA-
tagged wt ABCA1-expressing cells, whereas 50 μM cylcosporin A (CsA) pretreatment slightly reduced the apoA-I-binding in 
these cells. ALLN and CSA had no effect on apoAI-binding of the parental and mutant HA-ABCA1 expressing cells. Control - 
cells treated with vehicle.
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bition of the degradation pathway. To decrease the cell
surface appearance of the protein, Brefeldin A (BFA), an
inhibitor of trans-Golgi transport [39] was applied. Indi-
rect immunofluorescent labeling with anti-HA antibody
was performed with intact cells 4 h after the treatment
with ALLN and BFA, then studied by flow cytometry. Fig-
ures 7A and 7B show representative experiments with
HEK293H cells expressing wt and MM variant of the HA-
tagged ABCA1. Quantitative results are depicted in Figures
7C and 7D. A substantial alteration in the cell surface
expression of both variants was observed as compared to
non-treated cells. ALLN caused about 1.6-fold increase,
whereas BFA treatment resulted in 60% reduction in the
plasma membrane level of wt HA-ABCA1 (Figure 7C). It
is of note that the effects of drugs were slightly smaller in
cells expressing the MM variant of HA-ABCA1 as com-
pared to cells expressing the wt HA-ABCA1 (Figure 7D).
Similar to BFA, a general protein synthesis blocker,
cycloheximide also reduced the cell surface expression of
both ABCA1 variants; however, this drug substantially
affected cell viability (data not shown).
ApoA-I has also been demonstrated to increase ABCA1
expression by binding to the transporter and preventing it
from degradation [36,37]. As expected, apoA-I signifi-
cantly increased the cell surface expression of wt HA-
tagged ABCA1 (Figure 7C). The MM mutant ABCA1,
which was shown to be unable to bind apoA-I [29], exhib-
ited no alteration of the cell surface expression levels
when incubated with apoA-I (Figure 7D). These experi-
ments clearly demonstrate that our model system is suita-
ble to detect the effects of various substances on the cell
surface expression of either the functional or non-func-
tional variant of ABCA1.
In similar experiments, HA-ABCA1-expressing MDCKII
cells were treated with ALLN or BFA. Even though a wide
range of drug concentrations was tested, no marked
changes in the ABCA1 cell surface expression were seen in
these cells. Therefore, in further experiments HEK293H
cells expressing the HA-tagged ABCA1 variants were used.
Effect of different drugs on cell surface expression of 
ABCA1 variants
By having a verified test system, we studied the effect of
various drugs on the cell surface expression of ABCA1 var-
iants. We primarily tested the effect of pharmaceuticals
which are known to have cholesterol-lowering effects in
vivo, to see whether they also act through modifying the
cell surface appearance of ABCA1. These drugs included
atorvastatin, ezetimibe, and niacin [9], 40-45, as well as
calcium channel blockers, nifedipine and verapamil
[19,20]. In addition, we investigated the effect of
cyclosporin A and glyburide, which have previously been
reported to influence the plasma membrane level or func-
tion of ABCA1 [29,38]. The studied drugs were applied in
a wide concentration range with various incubation times.
As positive controls, ALLN and BFA were used to elevate
and reduce the ABCA1 cell surface expression, respec-
tively. The results are summarized in Table 1.
We found that atorvastatin (10-50 μM), niacin (0.1-1
mM), verapamil (10-50 μM) and nifedipine (30-100 μM)
had no significant effect on the plasma membrane level of
ABCA1 even in a wide concentration range. However, CsA
(10 μM) substantially elevated the cell surface expression
of wt HA-ABCA1 (Figure 7C) in accordance with previous
results indicating ABCA1 sequestration in the plasma
membrane by CsA [38]. It has not been shown yet
whether this effect of CsA is associated with the protein
function, therefore we performed similar experiments
with the non-functional mutant (MM) variant of ABCA1.
We found that CsA equally increased the ABCA1 cell sur-
face expression in wt and MM HA-ABCA1-expressing cells
(Figure 7C-D), thus the trapping effect of CsA is independ-
ent from ABCA1 function. Unexpectedly, ezetimibe (EZ),
a blocker of the intestinal cholesterol absorption, signifi-
cantly (by 20%) reduced the cell surface expression of wt
HA-ABCA1 (Figure 7C). Interestingly, this effect of EZ was
found to be associated with ABCA1 function, since no
reduction in the cell surface expression of the MM HA-
ABCA1 was seen in response to EZ treatment (Figure 7D).
Glyburide, which has previously been reported to inhibit
ABCA1-mediated cholesterol efflux and apoA-I binding
without altering the cell surface levels or total protein lev-
els of ABCA1 [29,46], had no effect of the plasma mem-
brane level of ABCA1 (see Table 1). However, at higher
concentrations a slight reduction in the ABCA1 cell sur-
face expression was observed in parallel with a substantial
decline in the cell viability in both wt and MM HA-
ABCA1-expressing cells. Treatment with 200-500 μM gly-
buride for 4 h resulted in 50% cell death in both cell types.
We also investigated the effect of plasma membrane cho-
lesterol levels on the cell surface expression of ABCA1 var-
iants. Treatment with 0.1-2.5 mM methyl-β-cyclodextrin
(CD), which results in membrane cholesterol depletion
[47], had no effect on the plasma membrane level of
either wild type or MM variant of HA-ABCA1 even in a
wide range of incubation time (20-240 min), although a
substantial reduction in the cell viability was observed.
Similarly, cholesterol overload by cholesterol-containing
CD treatment (0.1-2.5 mM, 20-240 min) did not alter the
cell surface expression of ABCA1 in either cell type.
Discussion
ABCA1 protein is involved in lipid metabolism in several
regards. This protein promotes reverse cholesterol trans-
port from the peripheral tissues. ABCA1, being located on
the basolateral surface of hepatocytes and intestinal cells,BMC Cell Biology 2009, 10:93 http://www.biomedcentral.com/1471-2121/10/93
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Effect of different drugs on the cell surface expression of HA-ABCA1 variants Figure 7
Effect of different drugs on the cell surface expression of HA-ABCA1 variants. Flow cytometry analysis of HEK293H 
cells expressing wild type or MM variant of HA-tagged ABCA1. (A, B) Representative histograms show indirect immunofluo-
rescent staining of intact cells, using anti-HA antibody (thick lines) or mouse IgG1 (isotype control, thin black line). Treatment 
with 50 μM ALLN (thick black line) substantially increased, whereas 5 mg/ml BFA (dotted line) reduced the cell surface expres-
sion level of both wild type (HA-WT) and mutant (HA-MM) HA-ABCA1 variants, as compared to cells treated with vehicle 
only (control, grey line). (C, D) Cell surface expression of wild type and MM mutant HA-ABCA1 variants in HEK293H cells 
treated with 50 μM ALLN, 5 mg/ml BFA, 10 μg/ml apoA-I, 10 μM CsA, or 50 μM EZ for 4 h. Relative expression levels were 
expressed as the geometric mean fluorescence intensities of drug-treated cells normalized to that of vehicle-treated samples 
(control). Each column represents the mean ± S.E.M. of at least 3 independent experiments. (* p < 0.005; n.s.: non-significant)
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has been shown to play a crucial role in the hepatic and
intestinal secretion of HDL [48]. In the present study we
generated and characterized a model system for the quan-
titative assessment of the plasma membrane level of
ABCA1. Inclusion of an extracellular hemagglutinin
epitope into ABCA1 enabled monitoring of its cell surface
expression by flow cytometry and confocal microscopy.
By using retroviral transduction we established mamma-
lian cell lines stably expressing functional and non-func-
tional HA-tagged ABCA1 variants. This experimental tool
allowed us to investigate the effect of different drugs on
cell surface expression of ABCA1.
In previous studies, the protein expression level and sub-
cellular localization of wild type ABCA1 and non-func-
tional mutant forms were found to be identical [27,31].
Similarly, in our model system, both the overall and the
plasma membrane expression levels of each HA-tagged
ABCA1 variant were comparable, as determined by West-
ern blotting and cell surface labeling (Figures 2B, 3).
ABCA1 has been reported to be localized to the basola-
teral membrane in polarized cells [32]. We found proper
subcellular localization for each HA-tagged ABCA1 vari-
ant (Figures 4, 5) in accordance with previous reports on
the untagged versions of the transporter [27].
Since the applicability and reproducibility of a cellular
model system requires stable protein expression levels, we
investigated the persistence of our transgene in various
cell lines. We found that ABCA1 expression remains stable
in MDCKII and HEK293H cells up to 50 and 20 passages,
respectively. Thus, our experimental test system substan-
tially surpasses previous attempts to generate cellular
models with ABCA1, since in those cases protein expres-
sion rapidly declined after a few passages [31]. We dem-
onstrated the applicability of our system to assess the cell
surface appearance of ABCA1 by using BFA and ALLN,
which have been reported to influence ABCA1 trafficking
and degradation (Figure 7A, B).
In agreement with previous reports [35,36], we demon-
strated the stabilizing effect of apoA-I on the HA-tagged
ABCA1 at the cell surface (Figure 7C). Furthermore, we
found that the cell surface levels of the Walker motif
mutant ABCA1 (MM), which fails to bind apoA-I (Figure
6B) [28,29], was unaffected by apoA-I (Figure 7D). This
observation is in line with previous findings demonstrat-
ing that binding of apoA-I is required for the apoA-I-medi-
ated increase of ABCA1 expression [29,37].
Table 1: Effect of various substances on the cell surface expression of wild type (HA-WT) and mutant (HA-MM) HA-ABCA1 variants
Drug Known effect ABCA1 cell surface expression
HA-WT HA-MM
ALLN Calpain inhibitor  (+ 60%)  (+ 30%)
ApoA-I cholesterol acceptor  (+ 30%) no effect
Atorvastatin cholesterol level lowering no effect no effect
Brefeldin A trans-Golgi transport inhibitor  (- 60%)  (- 40%)
Cycloheximide protein synthesis inhibitor  (- 30%) (viability ) (- 30%) (viability )
Cyclosporin A immunosuppressor  (+ 60%)  (+ 60%)
Ezetimibe inhibitor of intestinal cholesterol absorption  (- 20%) no effect
Glyburide ABCA1 inhibitor no effect no effect
Niacin cholesterol level lowering no effect no effect
Nifedipine Ca2+-channel blocker no effect no effect
Methyl-β-cyclodextrin cholesterol depletion no effect (viability ) no effect (viability )
Cholesterol-methyl-β-cyclodextrin cholesterol overloading no effect (viability ) no effect (viability )
Verapamil Ca2+-channel blocker no effect no effectBMC Cell Biology 2009, 10:93 http://www.biomedcentral.com/1471-2121/10/93
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In clinical trials, statins were highly effective in reducing
LDL-cholesterol, but only moderate effects were seen on
the HDL levels. Among a number of different statins, ator-
vastatin was the most effective and induced redistribution
in HDL subpopulations by increasing the fraction of
larger HDL particles [49]. Conflicting results were pub-
lished on the effect of statins on ABCA1 expression and
lipid efflux in various cellular systems. Wong et al. dem-
onstrated down-regulation of ABCA1 mRNA and protein
levels as well as reduction in the apoA-I-mediated choles-
terol efflux in response to statin treatment of PMA-
induced Thp-1 cells [14,15]. In contrast, another study
found that atorvastatin increased mRNA expression of
ABCA1 and promoted cholesterol efflux in the same cell
type [12]. In hepatoma cells, statins induced ABCA1
expression resulting in cholesterol and phospholipid
efflux to apoA-I [50]. These observations leave the ques-
tion open, whether statins influence apoA-I-dependent
cholesterol efflux solely by changing ABCA1 expression
levels or by modifying its subcellular trafficking and cell
surface appearance. Since our model system excludes tran-
scriptional regulation, our results revealed that atorvasta-
tin has no effect on the plasma membrane expression of
ABCA1.
Niacin has been reported to be one of the most potent
agents increasing HDL cholesterol levels [9], and to stim-
ulate ABCA1 expression and function in monocytic cell
lines via influencing the cAMP/PKA pathway [51]. By
investigating the effect of niacin in our system, we
observed no direct effect on cell surface appearance of
ABCA1 in accordance with previous observations on the
regulatory mechanism of niacin.
Calcium channel blockers have also been reported to
influence ABCA1 expression. Hasegawa et al. demon-
strated the role of different signaling pathways including
PKA, tyrosine kinase, and Janus kinase in ABCA1 expres-
sion modulation in response to various CCBs. They found
that some of the CCBs, e.g., aranidipine and efonidipine,
increase ABCA1 protein expression without altering the
mRNA level [20]. In contrast, Suzuki et al. demonstrated
a dose-dependent stimulatory effect of other CCBs, such
as verapamil, nifedipine, and nicardipine, on both the
mRNA and protein expression levels of ABCA1, resulting
in elevated cellular lipid release [19]. Our results do not
support these findings, since we observed no significant
effect on the plasma membrane level of ABCA1 in a wide
concentration range of verapamil and nifedipine.
Membrane cholesterol has been implicated to regulate
many membrane proteins, including several ABC trans-
porters, e.g. ABCB1 and ABCG2 [47,52,53]. Membrane
microdomains with high cholesterol content have been
suggested to play a role in such regulation [47]. However,
neither cholesterol overload nor depletion influenced
ABCA1 cell surface expression in our model system. It is
noteworthy that treatment with methyl-β-cyclodextrin
(CD) reduced, whereas cholesterol-loaded CD signifi-
cantly increased cell viability. The most plausible explana-
tion for this observation is that CD treatment makes the
cell membrane fragile and more sensitive to mechanical
stress. This notion should be taken in account in future
studies on ABCA1-expressing cells treated with CD.
We studied the effect of glyburide and CsA, which have
previously been reported to influence the plasma mem-
brane level or function of ABCA1 [29,38]. In accordance
with previous observations, glyburide had no effect on
ABCA1 plasma membrane appearance in our model sys-
tem [29], whereas CsA greatly increased the cell surface
level of ABCA1 (Figure 7C). ALLN elevated both ABCA1
cell surface expression and apoA-I binding, whereas CsA
reduced apoA-I binding despite the increased plasma
membrane level of ABCA1. This observation is line with a
previous report suggesting that CsA sequesters ABCA1 in
the plasma membrane [38]. The observation that cell sur-
face expression of the non-functional ABCA1 mutant
(MM) is also increased by CsA pretreatment clearly indi-
cates that the trapping effect of this drug is independent
from ABCA1 function.
Ezetimibe, a drug which is known to block the intestinal
cholesterol absorption, has not only an inhibitory effect
on several brush border membrane proteins, including
Niemann-Pick C1-like 1, scavenger receptor B-I and CD36
[54], but has also been reported to lower the mRNA level
of several other genes involved in lipid metabolism. The
transcription of ABCA1 is also reduced by EZ [55], but no
study has yet been reported on its effect on the cell surface
expression of ABCA1. Our model system allows us to
investigate the plasma membrane expression of ABCA1
independently from its transcriptional regulation. Strik-
ingly, we found that EZ significantly lowers the cell sur-
face expression of wt HA-ABCA1 (Figure 7C). Since no
reduction in the cell surface expression of the MM HA-
ABCA1 was seen in response to EZ treatment (Figure 7D),
the effect of EZ occurs only with a functional ABCA1, thus,
its effect is likely connected to a functional form of the
protein.
There are several possibilities to explain the lack of effect
of EZ on cell surface expression of the non-functional
MM-ABCA1 variant. It is theoretically possible but very
unlikely that EZ inhibits the trafficking of only the de novo
synthesized functional proteins. It is more plausible that
EZ influences the protein internalization and recycling to
the plasma membrane, since ABCA1 has been shown to
undergo a relatively rapid internalization and recycling to
the plasma membrane, which process is widely acceptedBMC Cell Biology 2009, 10:93 http://www.biomedcentral.com/1471-2121/10/93
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to require protein function [39,56]. Therefore, if EZ either
accelerates protein internalization or inhibits recycling,
and in the meantime MM-ABCA1 has a lower internaliza-
tion and recycling turnover compared to wild type, EZ
causes a smaller effect on the cell surface appearance of
the mutant transporter. This hypothesis is supported by
the observation that the effects of ALLN were also smaller
in HA-MM-ABCA1-expressing cells, as compared to wild
type HA-ABCA1. It is also possible that EZ accelerates
ABCA1 degradation, since the internalization itself is
dependent on the transporter function. This idea is not
supported by our recent observations using confocal
microscopy, when we found that following EZ treatment
the wt HA-ABCA1, but not the MM variant, accumulated
intracellularly in vesicles but not in lysosomes (data not
shown). Nevertheless, further studies are needed to reveal
the mechanism of EZ effect on the cell surface expression
of ABCA1.
Conclusions
In the current study, we have provided a model system
suitable for the quantitative assessment of the plasma
membrane level of ABCA1. We have shown that this test
system can be reliably applied for studying the effect of
various pharmaceuticals on the cell surface expression of
the transporter. Therefore, our model system provides a
new tool for acquiring more information on the post-
translational regulation, internalization, degradation and
recycling of the ABCA1 protein.
Methods
Plasmid constructs
For the generation of SsA1neoS vector, the full length wild
type human ABCA1 cDNA [57] was cloned into a bicis-
tronic retroviral SPsLdS vector [58], which was modified
to contain the neomycin resistance cassette (neo) as previ-
ously described [25]. A cassette containing the coding
sequence of an HA epitope (YPYDVPDY) was inserted
into the full-length human ABCA1 cDNA, between resi-
dues 207 and 208 [26]. For control experiments, a vector
containing only the neo cDNA was generated. The HA-
ABCA1 K939 M, K1952 M mutants were constructed in
the pBlscrSK- vector containing XhoI/NotI cassette from
the SsHAA1neoS vector. HA-ABCA1 K939 M was con-
structed by the overlap extension PCR technique using the
internal 5'-TGGCTGTGATCATCAAGGGC-3' and 5'-
CCAGGACGTCCGCTTCATCCAT-3' and external 5'-ATT-
GACATGGTGGTCGTCATCC-3' and 5'-GGATGACGAC-
CACCATGTCAAT-3' oligonucleotides. The external
primer pair includes AAG (lysine) to ATG (methionine)
single mutation and a new FokI restriction site (in bold).
The HA-ABCA1 K1952 M mutant was generated by using
5'-AGCCAAAAGCTTAAAGAACAAGATCTGGGTG-3' and
5'-CTCCTGTTAACATCTTGAAAGTTGATGACATC-
CCAGCC-3' oligonucleotides, which results in a lysine to
methionine mutation (in bold) and contains a GC substi-
tution (underlined) to create a new FokI restriction site.
The mutant constructs were verified by FokI digestion.
HA-ABCA1 variant containing double methionine substi-
tution was created by cassette exchange in pBlscrSK- vector
by using HindIII/HpaI digestion. After partial digestion of
each mutant construct in pBlscrSK- vector by XhoI/BamHI
enzymes the fragments were transferred into SsHAA1neoS
vector and verified by sequencing.
Cell culturing
Phoenix-eco [59] was a gift from G. Nolan (Department
of Pharmacology, Stanford University, Stanford, CA);
PG13 retrovirus producing cells [60], HepG2, Thp-1, and
MDCKII cells were obtained form the ATCC (Manassas,
VA). HEK293H cells were purchased from Invitrogen.
Most cell lines were grown in DMEM containing 10%
FCS, whereas HepG2 were cultured in DMEM and F12
(1:1) + 10% FCS medium. Thp-1 cells were maintained in
RPMI + 10% FCS medium, and pretreated with 2 nM PMA
for 24 h. Human monocytes were isolated from periph-
eral blood of healthy subjects, as previously described
[61], and cultured in DMEM containing 10% FCS for 5
days. ABCA1 expression was induced in both PMA-pre-
treated Thp-1 cells and monocyte-derived macrophages
by the addition of a synthetic LXR agonist, T0901317 (1
μM, Alexis Biochemicals) 8 h prior to studies.
Generation of cell lines stably expressing ABCA1 variants
Retroviral particles and cell lines stably expressing the
ABCA1 variants were generated as described previously
[25,30] with some modifications. Briefly, the Phoenix-eco
packaging cell line was transfected by calcium phosphate
coprecipitation (Invitrogen). The cell-free viral superna-
tant was collected 24 and 48 hours after transfection and
immediately used to transduce PG13 cells. The transduc-
tion of PG13 cells was repeated on the following day.
HEK293H and MDCKII cells were transduced with viral
supernatant collected from PG13 packaging cells 24 and
48 hours after transduction. The target cells were then
selected with 0.5 mg/ml and 0.8 mg/ml G418 for
HEK293H and MDCKII cells, respectively. Single-cell
clones of transduced MDCKII cells were isolated by limit-
ing dilutions on 96-well plates under continuous G418
selection. In contrast, HEK293H cells were labeled with
direct anti-HA antibody and sorted by a FACSAria (Becton
Dickinson) cell sorter. To reduce the heterogeneity, a sub-
sequent cell sorting was performed.
RNA isolation and real time RT-PCR
Total RNA was isolated by a single-step method using Tri-
Zol (Invitrogen). The purity of the RNA preparation was
checked by measuring the absorbance ratio at 260/280
nm. For each reaction 1 μg total RNA was reverse-tran-
scribed into cDNA according to the manufacturer's proto-BMC Cell Biology 2009, 10:93 http://www.biomedcentral.com/1471-2121/10/93
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col (Promega) using random hexamer oligonucleotides.
The resulting cDNA was then subjected to real-time quan-
titative PCR (Light Cycler 480 II, Roche), 45 cycles of
95°C for 30 s, 58°C for 1 s and 72°C for 1 s by using spe-
cific primers to detect human ABCA1 cDNA, but not the
genomic ABCA1 sequence. Oligonucleotides designed for
PCR analysis of ABCA1 or housekeeping Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) cDNAs were: 5-
ACAAGATGCTGAGGGCTGAT-3 and 5-CCCAAGACTAT-
GCAGCAATG-3 or 5-GAAGGTGAAGGTCGGAGTCA-3
and 5-GACAAGCTTCCCGTTCTCAG-3, respectively. PCRs
contained 3 mM MgCl2, 0.25 μM from ABCA1 and 0.5 μM
from GAPDH forward and reverse primers, and 5 μl Light-
Cycler DNA Master SYBR Green I (2×, Roche). Before
amplification, a preincubation step (60 seconds at 95°C)
was performed to activate FastStart DNA polymer and to
ensure complete denaturation of the cDNA. Following the
last cycle, melting curve analysis was carried out to specify
the integrity and purity of the amplicons. Amplification
profiles were analyzed using the Fit Points and 2nd Deriv-
ative Maximum calculation described in the LightCycler
Relative Quantification Software. The comparative Ct
method was used to quantify transcript levels and to nor-
malize for GAPDH expression.
Western blot analysis
Preparation of whole cell lysates and immunoblotting
were performed as described previously [62] with some
modifications. Cell were suspended in 2× Laemmli buffer
and sonicated for 5 seconds at 4°C. 15 μg and 40 μg of
protein per well from HEK293H cells and MDCKII cells,
respectively, were loaded onto a Laemmli-type 6% SDS-
polyacrylamide gel, separated, and blotted onto PVDF
membranes. Immunodetection was performed by using
an anti-HA monoclonal (HA.11, BabCo, 1:3000) or rabbit
polyclonal anti-ABCA1 (Abcam, 1:250) antibodies. A
HRP-conjugated goat anti-mouse or anti-rabbit IgG sec-
ondary antibody (Jackson Immunoresearch, 1:10.000),
and enhanced chemiluminescence (ECL) technique was
applied. For loading control, a mouse anti-Na+/K+ ATPase
antibody (BioMol, 1:1000) was used.
Confocal microscopy
For immunolocalization studies, HEK293H cells were
seeded onto eight-well Lab-Tek II Chambered Coverglass
(Nalge Nunc) at 5 × 104 per well cell density, and grown
for 2 days. For plasma membrane staining, the cells were
gently fixed with 1% paraformaldehyde (PFA) for 5 min
at room temperature, and incubated with 5 μg/ml
AlexaFluor633-conjugated wheat germ agglutinin (WGA,
Invitrogen) for 10 min at room temperature. For lysosome
staining, the living cells were subjected to LysoTracker Red
(Invitrogen) in culturing medium for 30 min at 37°C.
After marker staining the cells were fixed and permeabi-
lized with 8% PFA for 15 min at room temperature, and
labeled with anti-HA (HA.11, MMS-101R BabCo, 1:500)
antibody. To label the Golgi-apparatus and endosomes,
double-labeling was performed using rabbit anti-Giantin
(Abcam, 1:500) and anti-EEA1 antibodies (1:250),
respectively, as described previously [61]. For secondary
antibodies AlexaFluor-488-conjugated anti-mouse IgG
and AlexaFluor-594-conjugated anti-rabbit IgG antibod-
ies (Invitrogen, 1:250) were used. After immunolabeling
the samples were counterstained with 1 μM DAPI for 10
min at room temperature.
For subcellular localization studies in polarized cells, the
MDCKII cells were seeded at 5 × 105 cells/cm2 density on
6.5-mm Transwell Col filters (pore diameter 0.4, Corning
Costar) previously coated with 0.03 mg/ml Vitrogen
(Cohesion Technologies). The cultures were regularly
washed with culturing medium to remove cell debris.
Studies were carried out with confluent cultures 10 days
after seeding. The cultures were permeabilized and
labeled with anti-HA (HA.11, MMS-101R BabCo, 1:500)
and anti-Na+/K+ ATPase (Abcam, 1:250) antibodies, as
previously described [61]. AlexaFluor-488-conjugated
anti-mouse IgG and AlexaFluor-647-conjugated anti-
chicken IgG secondary antibodies (Invitrogen, 1:250)
were used.
The blue, green, red and far red fluorescence of stained
samples was studied by an Olympus FV500-IX confocal
laser scanning microscope using a PLAPO 60× (1.4) oil
immersion objective (Olympus) at 405, 488, 543, and
633 nm excitations.
Cholesterol efflux measurement
Cholesterol efflux measurement was performed as
described previously [34]. Briefly, near confluent
HEK293H and non-polarized MDCKII cultures grown on
6 well plates were labeled with 100 nM (4 μCi/ml) 3H-
cholesterol (PerkinElmer) at 37°C for 24 hours in serum-
free DMEM containing 2 mg/ml fatty acid free BSA. The
media were then replaced with fresh DMEM/BSA in the
presence or absence of 15 μg/ml of apoA-I and incubated
at 37°C for 24 hours. Supernatants were collected and
spun down to remove cellular material. The pellets and
the cell layers were lysed in 2% SDS and 1 M NaOH. The
radioactivity of both samples was measured by liquid
scintillation; the cholesterol efflux was expressed as the
percentage of total (extruded plus cellular) 3H-choles-
terol. The apoA-I-dependent efflux was obtained from the
difference of the effluxes measured in the presence and
absence of apoA-I.
Cell surface expression studies
For cell surface expression studies, the cells were detached
by trypsinization and after washing steps blocked for 10
min at room temperature in phosphate-buffered salineBMC Cell Biology 2009, 10:93 http://www.biomedcentral.com/1471-2121/10/93
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containing 2 mg/ml bovine serum albumin (BSA/PBS).
The samples were then incubated for 40 min at room tem-
perature with anti-HA antibody (HA.11, MMS-101R
BabCo, 1:250 in BSA/PBS). After subsequent washing
steps AlexaFluor-488-conjugated anti-mouse IgG second-
ary antibody (Invitrogen, 1:500 in BSA/PBS) was applied
for 40 min at room temperature. As an isotype control a
mouse IgG1 (1:10) from Sigma-Aldrich was used. The cell
surface expression of the HA-ABCA1 variants was detected
by flow cytometry (Becton Dickinson FACS Calibur).
When the modifying effect of various drugs was studied,
the cells in the culture dish were pretreated for 4 hours
with the following substances: 50 μM ALLN, 10 μg/ml
apoA-I (Calbiochem), 10-50 μM atorvastatin (Pfizer), 5
μg/ml BFA, 10-50 μM ezetimibe (Schering-Plough), 0.1-1
mM niacin, 10-50 μM verapamil, 30-100 μM nifedipine,
50-500 μM glyburide, 10-50 μM cyclosporin A, 100 μg/ml
cycloheximide, 0.1-2.5 mM random methylated beta
cyclodextrin (CD, CycloLab), or 0.1-2.5 mM CD
preloaded with 4.4% cholesterol (CycloLab). The materi-
als were obtained from Sigma-Aldrich if not indicated
otherwise. After treatment, cells were trypsinized, pre-
stained for 2 min with 10 mg/ml propidium-iodide, and
gently fixed with PFA for 10 min. Immunofluorescent
staining of drug-treated cells was performed at 4 C. Rela-
tive expression levels were expressed as the ratio of geo-
metric mean fluorescence of drug-treated and the vehicle-
treated samples. For statistical analysis Student's t test was
used.
ApoA-I binding
ApoA-I conjugation and binding-experiments were per-
formed as described previously [28] with minor modifica-
tions. Briefly, apoA-I was conjugated to the fluorochrome
Cy5 (PA25001, Amersham Pharmacia Biotech) according
to the recommendation of the manufacturer. For all
experiments the labeled apoA-I (apoA-I-Cy5) was diluted
in binding buffer (1.8 mM CaCl2, 1 mM MgCl2, 5 mM
KCl, 150 mM NaCl, 10 mM HEPES, pH 7.4), and aggre-
gates were removed by ultracentrifugation for 30 min at
100,000 g. Binding was performed in the presence of 20
μg/ml of apoA-I-Cy5 for 1 h at 4°C on 5 × 105 cells
detached by trypsinization. After the incubation, cells
were rapidly washed and not fixed with 1% PFA. For stud-
ying the effect of ALLN and CsA, the cells were pretreated
with same concentrations of drugs as in the cell surface
expression studies. After incubation for 4 hours cells were
washed and apoA-I binding experiment was performed.
The apoA-I binding was detected by flow cytometry (Bec-
ton Dickinson FACS Calibur) and analyzed by CellQuest
Pro software. Binding data are calculated from the median
of apoA-I-Cy5 fluorescence intensity.
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